Caricamento...
SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy
Most patients with COVID-19 lack antibody to SARS-CoV-2 in the first 10 days of illness while the virus drives disease pathogenesis. SARS-CoV-2 antibody deficiency in the setting of a tissue viral burden suggests that using an antibody as a therapeutic agent would augment the antiviral immune respon...
Salvato in:
| Pubblicato in: | J Clin Invest |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Clinical Investigation
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7524464/ https://ncbi.nlm.nih.gov/pubmed/32634126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI139760 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|